How to test for Helicobacter pylori in 2005

Article Type
Changed
Tue, 09/25/2018 - 09:43
Display Headline
How to test for Helicobacter pylori in 2005
Article PDF
Author and Disclosure Information

Nimish Vakil, MD
University of Wisconsin Medical School, Milwaukee, and Marquette College of Health Sciences, Milwaukee, WI

A. Mark Fendrick, MD
Division of General Medicine and the Consortium for Health Outcomes, Innovation, and Cost-Effectiveness Studies, University of Michigan Health System, Ann Arbor, MI

Dr. Vakil has received grant/research support from AstraZeneca Pharmaceuticals, Medtronic, Novartis, and Pfizer; has served as a consultant to AstraZeneca, Medtronic, Meridian Bioscience, and Novartis; and is on the speakers’ bureaus of AstraZeneca, Novartis, and TAP Pharmaceutical Products.

Dr. Fendrick has served as a consultant to Meridian Bioscience.

Publications
Page Number
S8-S13
Author and Disclosure Information

Nimish Vakil, MD
University of Wisconsin Medical School, Milwaukee, and Marquette College of Health Sciences, Milwaukee, WI

A. Mark Fendrick, MD
Division of General Medicine and the Consortium for Health Outcomes, Innovation, and Cost-Effectiveness Studies, University of Michigan Health System, Ann Arbor, MI

Dr. Vakil has received grant/research support from AstraZeneca Pharmaceuticals, Medtronic, Novartis, and Pfizer; has served as a consultant to AstraZeneca, Medtronic, Meridian Bioscience, and Novartis; and is on the speakers’ bureaus of AstraZeneca, Novartis, and TAP Pharmaceutical Products.

Dr. Fendrick has served as a consultant to Meridian Bioscience.

Author and Disclosure Information

Nimish Vakil, MD
University of Wisconsin Medical School, Milwaukee, and Marquette College of Health Sciences, Milwaukee, WI

A. Mark Fendrick, MD
Division of General Medicine and the Consortium for Health Outcomes, Innovation, and Cost-Effectiveness Studies, University of Michigan Health System, Ann Arbor, MI

Dr. Vakil has received grant/research support from AstraZeneca Pharmaceuticals, Medtronic, Novartis, and Pfizer; has served as a consultant to AstraZeneca, Medtronic, Meridian Bioscience, and Novartis; and is on the speakers’ bureaus of AstraZeneca, Novartis, and TAP Pharmaceutical Products.

Dr. Fendrick has served as a consultant to Meridian Bioscience.

Article PDF
Article PDF
Related Articles
Page Number
S8-S13
Page Number
S8-S13
Publications
Publications
Article Type
Display Headline
How to test for Helicobacter pylori in 2005
Display Headline
How to test for Helicobacter pylori in 2005
Citation Override
Cleveland Clinic Journal of Medicine 2005 May;72(suppl 2):S8-S13
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Pitfalls, pearls, and practicalities in the diagnosis of Helicobacter pylori infection

Article Type
Changed
Tue, 09/25/2018 - 09:44
Display Headline
Pitfalls, pearls, and practicalities in the diagnosis of Helicobacter pylori infection
Article PDF
Author and Disclosure Information

Gary Falk, MD
Department of Gastroenterology & Hepatology, Cleveland Clinic Foundation, Cleveland, OH

Leonard Ehrlich, MD
George Washington University School of Medicine, Washington, DC

A. Mark Fendrick, MD
Division of General Medicine, University of Michigan Health System, Ann Arbor, Ml

M. Brian Fennerty, MD
Division of Gastroenterology, Oregon Health & Science University, Portland, OR

Ben Gold, MD
Division of Pediatric Gastroenterology and Nutrition, Emory University School of Medicine, Atlanta, GA

Nimish Vakil, MD
University of Wisconsin Medical School and Marquette College of Health Sciences, Milwaukee, WI

Derek van Amerongen, MD, MS
Chief Medical Officer, Humana Health Plan of Ohio, Cincinnati, OH

David Wyatt, MD
Eagles Landing Family Practice, McDonough, GA

Gary Falk, MD, has served as a consultant to AstraZeneca Pharmaceuticals and Meridian Bioscience.

Brian Fennerty, MD, has served as a consultant to AstraZeneca Pharmaceuticals, Eisai, Meridian Bioscience, Santarus, and TAP Pharmaceutical Products.

Ben Gold, MD, has served as a consultant to AstraZeneca Pharmaceuticals, Meridian Bioscience, Meretek Diagnostics, and TAP Pharmaceutical Products.

Nimish Vakil, MD, has received grant/research support from AstraZeneca Pharmaceuticals, Medtronic, Novartis, and Pfizer; has served as a consultant to AstraZeneca, Medtronic, Meridian Bioscience, and Novartis; and is on the speakers’ bureaus of AstraZeneca, Novartis, and TAP Pharmaceutical Products.

Leonard Ehrlich, MD, A. Mark Fendrick, MD, Derek van Amerongen, MD, and David Wyatt, MD, have served as consultants to Meridian Bioscience.

Publications
Page Number
S14-S21
Author and Disclosure Information

Gary Falk, MD
Department of Gastroenterology & Hepatology, Cleveland Clinic Foundation, Cleveland, OH

Leonard Ehrlich, MD
George Washington University School of Medicine, Washington, DC

A. Mark Fendrick, MD
Division of General Medicine, University of Michigan Health System, Ann Arbor, Ml

M. Brian Fennerty, MD
Division of Gastroenterology, Oregon Health & Science University, Portland, OR

Ben Gold, MD
Division of Pediatric Gastroenterology and Nutrition, Emory University School of Medicine, Atlanta, GA

Nimish Vakil, MD
University of Wisconsin Medical School and Marquette College of Health Sciences, Milwaukee, WI

Derek van Amerongen, MD, MS
Chief Medical Officer, Humana Health Plan of Ohio, Cincinnati, OH

David Wyatt, MD
Eagles Landing Family Practice, McDonough, GA

Gary Falk, MD, has served as a consultant to AstraZeneca Pharmaceuticals and Meridian Bioscience.

Brian Fennerty, MD, has served as a consultant to AstraZeneca Pharmaceuticals, Eisai, Meridian Bioscience, Santarus, and TAP Pharmaceutical Products.

Ben Gold, MD, has served as a consultant to AstraZeneca Pharmaceuticals, Meridian Bioscience, Meretek Diagnostics, and TAP Pharmaceutical Products.

Nimish Vakil, MD, has received grant/research support from AstraZeneca Pharmaceuticals, Medtronic, Novartis, and Pfizer; has served as a consultant to AstraZeneca, Medtronic, Meridian Bioscience, and Novartis; and is on the speakers’ bureaus of AstraZeneca, Novartis, and TAP Pharmaceutical Products.

Leonard Ehrlich, MD, A. Mark Fendrick, MD, Derek van Amerongen, MD, and David Wyatt, MD, have served as consultants to Meridian Bioscience.

Author and Disclosure Information

Gary Falk, MD
Department of Gastroenterology & Hepatology, Cleveland Clinic Foundation, Cleveland, OH

Leonard Ehrlich, MD
George Washington University School of Medicine, Washington, DC

A. Mark Fendrick, MD
Division of General Medicine, University of Michigan Health System, Ann Arbor, Ml

M. Brian Fennerty, MD
Division of Gastroenterology, Oregon Health & Science University, Portland, OR

Ben Gold, MD
Division of Pediatric Gastroenterology and Nutrition, Emory University School of Medicine, Atlanta, GA

Nimish Vakil, MD
University of Wisconsin Medical School and Marquette College of Health Sciences, Milwaukee, WI

Derek van Amerongen, MD, MS
Chief Medical Officer, Humana Health Plan of Ohio, Cincinnati, OH

David Wyatt, MD
Eagles Landing Family Practice, McDonough, GA

Gary Falk, MD, has served as a consultant to AstraZeneca Pharmaceuticals and Meridian Bioscience.

Brian Fennerty, MD, has served as a consultant to AstraZeneca Pharmaceuticals, Eisai, Meridian Bioscience, Santarus, and TAP Pharmaceutical Products.

Ben Gold, MD, has served as a consultant to AstraZeneca Pharmaceuticals, Meridian Bioscience, Meretek Diagnostics, and TAP Pharmaceutical Products.

Nimish Vakil, MD, has received grant/research support from AstraZeneca Pharmaceuticals, Medtronic, Novartis, and Pfizer; has served as a consultant to AstraZeneca, Medtronic, Meridian Bioscience, and Novartis; and is on the speakers’ bureaus of AstraZeneca, Novartis, and TAP Pharmaceutical Products.

Leonard Ehrlich, MD, A. Mark Fendrick, MD, Derek van Amerongen, MD, and David Wyatt, MD, have served as consultants to Meridian Bioscience.

Article PDF
Article PDF
Related Articles
Page Number
S14-S21
Page Number
S14-S21
Publications
Publications
Article Type
Display Headline
Pitfalls, pearls, and practicalities in the diagnosis of Helicobacter pylori infection
Display Headline
Pitfalls, pearls, and practicalities in the diagnosis of Helicobacter pylori infection
Citation Override
Cleveland Clinic Journal of Medicine 2005 May;72(suppl 2):S14-S21
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 09/25/2018 - 09:15
Un-Gate On Date
Tue, 09/25/2018 - 09:15
Use ProPublica
CFC Schedule Remove Status
Tue, 09/25/2018 - 09:15
Article PDF Media

Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy

Article Type
Changed
Fri, 12/07/2018 - 12:23
Display Headline
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
Article PDF
Author and Disclosure Information

A. Mark Fendrick, MD
Department of Internal Medicine, Health Management and Policy, Division of General Medicine, University of Michigan.

Correspondence: A. Mark Fendrick, MD, Associate Professor, Division of General Medicine, Department of Internal Medicine, Health Management and Policy, University of Michigan, 300 North Ingalls Bldg, Rm 7E06, Box 0429, Ann Arbor, MI 48109-0429; e-mail: amfen@umich.edu

The author has indicated that he has been a consultant for Merck, AstraZeneca, and TAP and is on the speakers’ bureaus of Merck and TAP.

Publications
Page Number
SI59-SI64
Author and Disclosure Information

A. Mark Fendrick, MD
Department of Internal Medicine, Health Management and Policy, Division of General Medicine, University of Michigan.

Correspondence: A. Mark Fendrick, MD, Associate Professor, Division of General Medicine, Department of Internal Medicine, Health Management and Policy, University of Michigan, 300 North Ingalls Bldg, Rm 7E06, Box 0429, Ann Arbor, MI 48109-0429; e-mail: amfen@umich.edu

The author has indicated that he has been a consultant for Merck, AstraZeneca, and TAP and is on the speakers’ bureaus of Merck and TAP.

Author and Disclosure Information

A. Mark Fendrick, MD
Department of Internal Medicine, Health Management and Policy, Division of General Medicine, University of Michigan.

Correspondence: A. Mark Fendrick, MD, Associate Professor, Division of General Medicine, Department of Internal Medicine, Health Management and Policy, University of Michigan, 300 North Ingalls Bldg, Rm 7E06, Box 0429, Ann Arbor, MI 48109-0429; e-mail: amfen@umich.edu

The author has indicated that he has been a consultant for Merck, AstraZeneca, and TAP and is on the speakers’ bureaus of Merck and TAP.

Article PDF
Article PDF
Page Number
SI59-SI64
Page Number
SI59-SI64
Publications
Publications
Article Type
Display Headline
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
Display Headline
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
Citation Override
Cleveland Clinic Journal of Medicine 2002 April;69(suppl 1):SI59-SI64
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media